AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27813466 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 112
Study 26422094 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 0.25 mg/kg
Number of subjects: 50
Study 26422094 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 1 mg/kg
Number of subjects: 50
Study 23308394 — intervention group
Group type: EXPERIMENTAL
Intervention: Grains of paradise extract (40 mg)
Number of subjects: 19
Study 23308394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22097200 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianggan Capsule (QC) for 6 months
Number of subjects: 70
Study 22097200 — intervention group
Group type: COMPARATOR
Intervention: Control group (glucurone and compound vitamin B) for 6 months
Number of subjects: 70
Study 19438984 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 39
Study 16895135 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX) - 300 IU injected into adductor and medial hamstring muscle groups
Number of subjects: 0
Study 16895135 — intervention group
Group type: COMPARATOR
Intervention: Johnstone pressure splint (JPS) - administered for 30 minutes 3 days per week
Number of subjects: 0
Study 14659974 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Pycnogenol for 12 weeks
Number of subjects: 58
Study 14659974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11697230 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital two-dimensional presentation of basic brain anatomy
Number of subjects: 36
Study 11697230 — intervention group
Group type: COMPARATOR
Intervention: Digital three-dimensional presentation of basic brain anatomy
Number of subjects: 36
Study 9439087 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 7
Study 9439087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7951099 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha 300 or 450 iu/kg subcutaneously thrice weekly for 2 weeks
Number of subjects: 11
Study 2085982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol 3 g
Number of subjects: 158
Study 2085982 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 3 g
Number of subjects: 158
Study 354147 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (500 mg daily, total dose 30 g)
Number of subjects: 0
Study 354147 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (1,000 mg daily, total dose 60 g)
Number of subjects: 0
Study 30784362 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECEDE model-based educational intervention
Number of subjects: 172
Study 30784362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 172
Study 27889546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L PEG-Asc
Number of subjects: 200
Study 26431720 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus HVHF (Cascade group)
Number of subjects: 60
Study 26431720 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control group)
Number of subjects: 60
Study 23795656 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled angiographic follow-up (SAF)
Number of subjects: 3404
Study 21457558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 79
Study 21457558 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 79
Study 19824561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Tri-S Bond
Number of subjects: 0
Study 19824561 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond
Number of subjects: 0
Study 19824561 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 0
Study 17090981 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with gemcitabine
Number of subjects: 60
Study 17090981 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with 5-fluorouracil
Number of subjects: 60
Study 14727149 — intervention group
Group type: EXPERIMENTAL
Intervention: Full course of oral levofloxacin (500 mg q12 h)
Number of subjects: 129
Study 14727149 — intervention group
Group type: COMPARATOR
Intervention: Intravenous-to-oral sequential therapy (intravenous ceftriaxone 2 g q24 h with or without clarithromycin 500 mg q12 h followed by oral beta-lactam)
Number of subjects: 129
Study 14727149 — intervention group
Group type: EXPERIMENTAL
Intervention: Full course of oral levofloxacin
Number of subjects: 129
Study 14727149 — intervention group
Group type: COMPARATOR
Intervention: Intravenous-to-oral sequential therapy
Number of subjects: 129
Study 11461805 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drug (possibly at different dosages)
Number of subjects: 0
Study 11461805 — intervention group
Group type: COMPARATOR
Intervention: Placebo or pseudo-placebo control
Number of subjects: 0
Study 11461805 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of the study drug
Number of subjects: 0
Study 11461805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of the study drug
Number of subjects: 0
Study 9066005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin infusion in ACEI-treated patients
Number of subjects: 17
Study 9066005 — intervention group
Group type: COMPARATOR
Intervention: Bradykinin infusion in placebo-treated patients
Number of subjects: 17
Study 9066005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin infusion
Number of subjects: 17
Study 9066005 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI treatment
Number of subjects: 17
Study 7526067 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg idrapril
Number of subjects: 8
Study 7526067 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg idrapril
Number of subjects: 8
Study 7526067 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg idrapril
Number of subjects: 8
Study 7526067 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg idrapril (oral)
Number of subjects: 8
Study 7526067 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg captopril
Number of subjects: 8
Study 7526067 — intervention group
Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 8
Study 7526067 — intervention group
Group type: COMPARATOR
Intervention: intravenous placebo
Number of subjects: 8
Study 3443046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepronine-lysine salt treatment
Number of subjects: 0
Study 3443046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28856925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone–patellar tendon–bone (BTB) grafts
Number of subjects: 100
Study 28856925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT) grafts
Number of subjects: 100
Study 28856925 — intervention group
Group type: COMPARATOR
Intervention: Both groups (BTB and HT)
Number of subjects: 100
Study 26754182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the PC 6 acupuncture point for 14 seconds (300 mW, energy density 4 J/cm²)
Number of subjects: 25
Study 26754182 — intervention group
Group type: COMPARATOR
Intervention: Control group (simulated laser application)
Number of subjects: 25
Study 24943987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (community pharmacist intervention)
Number of subjects: 395
Study 24943987 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 395
Study 23286297 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture treatment
Number of subjects: 0
Study 23286297 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized acupuncture treatment
Number of subjects: 0
Study 23286297 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19399583 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative supplement of carbohydrate and branched-chain amino acid-enriched nutrient mixture
Number of subjects: 26
Study 19399583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative supplementation)
Number of subjects: 26
Study 17976963 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate beer consumption for 30 days
Number of subjects: 57
Study 17976963 — intervention group
Group type: COMPARATOR
Intervention: Alcohol abstention for 30 days
Number of subjects: 57
Study 15871443 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke exposure (ETS)
Number of subjects: 57
Study 15871443 — intervention group
Group type: COMPARATOR
Intervention: No environmental tobacco smoke exposure (unexposed)
Number of subjects: 57
Study 15871443 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-asthmatic children
Number of subjects: 57
Study 15871443 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic children
Number of subjects: 57
Study 12529343 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based adjuvant chemotherapy
Number of subjects: 925
Study 12529343 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 925
Study 10738097 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR live oral cholera vaccine
Number of subjects: 67508
Study 10738097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67508
Study 8855176 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen, 3 MU three times per week for 6 months
Number of subjects: 21
Study 8855176 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose, 6 MU three times per week
Number of subjects: 21
Study 8855176 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended duration, 12 months vs. 6 months at 3 MU
Number of subjects: 21
Study 8855176 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended duration, 12 months vs. 6 months at 6 MU
Number of subjects: 21
Study 8855176 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of interferon treatment for acute hepatitis C
Number of subjects: 21
Study 1891951 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine (PRP-D)
Number of subjects: 0
Study 1891951 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine (PRP-D or HbOC)
Number of subjects: 0
Study 1891951 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccines (PRP-D, HbOC, PRP-T)
Number of subjects: 0
Study 6671926 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (582 mg)
Number of subjects: 5
Study 6671926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin from bacampicillin (800 mg)
Number of subjects: 5
Study 31444999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg daily
Number of subjects: 15
Study 30196134 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Number of subjects: 0
Study 30196134 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey results indicating practice change
Number of subjects: 0
Study 30196134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose and fractionation schedule
Number of subjects: 0
Study 26924549 — intervention group
Group type: EXPERIMENTAL
Intervention: BioHyalux
Number of subjects: 88
Study 26924549 — intervention group
Group type: COMPARATOR
Intervention: Restylane
Number of subjects: 88
Study 25286174 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based HIV prevention intervention
Number of subjects: 99
Study 25286174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 22424025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 300 mg
Number of subjects: 0
Study 22424025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 0
Study 22424025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 0
Study 22424025 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (concomitant treatment)
Number of subjects: 0
Study 22424025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19568958 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan combined with 5-fluorouracil and folinic acid (IF arm)
Number of subjects: 333
Study 19568958 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin with 5-fluorouracil (CF arm)
Number of subjects: 333
Study 17499999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg kg(‐1) after induction of anaesthesia
Number of subjects: 39
Study 17499999 — intervention group
Group type: COMPARATOR
Intervention: Saline as placebo
Number of subjects: 39
Study 15020614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine 100 mg/m2 weekly for 3 weeks
Number of subjects: 229
Study 15020614 — intervention group
Group type: COMPARATOR
Intervention: DTIC 250 mg/m2/d for 5 consecutive days every 4 weeks
Number of subjects: 229
Study 15020614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine
Number of subjects: 229
Study 15020614 — intervention group
Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 229
Study 15020614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine and DTIC
Number of subjects: 229
Study 12499030 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel/Ethinyl Estradiol (DSG/EE)
Number of subjects: 77
Study 12499030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine iron and folate supplementation
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin determination late in pregnancy
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for asymptomatic bacteriuria by urine culture or dipstick
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic screening and treatment of syphilis
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtaining a history of difficult labor in multipara or height in nullipara
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version at term
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine measurement of fundal height
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of maternal physical strain
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis and treatment of tuberculosis
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria prophylaxis
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate tetanus immunization
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal and perinatal Zidovudine in HIV-positive mothers
Number of subjects: 0
Study 10075217 — intervention group
Group type: EXPERIMENTAL
Intervention: One vaginal examination during pregnancy
Number of subjects: 0
Study 7645180 — intervention group
Group type: EXPERIMENTAL
Intervention: proxodolol
Number of subjects: 105
Study 7645180 — intervention group
Group type: EXPERIMENTAL
Intervention: proxodolol combined with pilocarpine and/or klofelin
Number of subjects: 105
Study 2650698 — intervention group
Group type: EXPERIMENTAL
Intervention: High fish intake
Number of subjects: 0
Study 2650698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low saturated fat diet
Number of subjects: 0
Study 2650698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating fish once or twice a week
Number of subjects: 0
Study 2650698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of fish consumption
Number of subjects: 0
Study 322693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide
Number of subjects: 0
Study 322693 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate
Number of subjects: 0
Study 322693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17‐butyrate
Number of subjects: 0
Study 322693 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurandrenolone
Number of subjects: 0
Study 322693 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study 30946156 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle diet and exercise intervention
Number of subjects: 107
Study 30946156 — intervention group
Group type: EXPERIMENTAL
Intervention: increased physical activity (walking an additional 10,000 steps per day)
Number of subjects: 107
Study 28351156 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Phytoestrogen (EX + PHY)
Number of subjects: 31
Study 28351156 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Placebo (EX + PL)
Number of subjects: 31
Study 28351156 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EX + PHY and EX + PL)
Number of subjects: 31
Study 25939436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone for 21 days in addition to conventional heart failure medication
Number of subjects: 110
Study 23435927 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin(®)), ≤ 50 U per eye, flexible doses, flexible injection intervals (minimum of 6 weeks)
Number of subjects: 102
Study 23435927 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin(®))
Number of subjects: 102
Study 21796089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation© technique (3 sessions of 30 minutes each, every five days for two weeks)
Number of subjects: 18
Study 21796089 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (10 sessions of 30 minutes each, five days a week for two consecutive weeks of neck exercises plus mobilization)
Number of subjects: 18
Study 21796089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation© technique
Number of subjects: 18
Study 19181730 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal peer support worker service (1140 women)
Number of subjects: 2511
Study 19181730 — intervention group
Group type: COMPARATOR
Intervention: Standard care (1371 women)
Number of subjects: 2511
Study 17315084 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 139
Study 17315084 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 139
Study 15038622 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive BP-lowering group (home systolic BP < 125 mmHg and diastolic < 80 mmHg)
Number of subjects: 546
Study 15038622 — intervention group
Group type: COMPARATOR
Intervention: Less intensive BP-lowering group (home systolic/diastolic BP within the range 134-125/84-80 mmHg)
Number of subjects: 546
Study 15038622 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Ca-A)
Number of subjects: 546
Study 15038622 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I)
Number of subjects: 546
Study 15038622 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonist (ARB)
Number of subjects: 546
Study 11755558 — intervention group
Group type: EXPERIMENTAL
Intervention: No bladder flap formation (study group)
Number of subjects: 102
Study 11755558 — intervention group
Group type: COMPARATOR
Intervention: Bladder flap formation (control group)
Number of subjects: 102
Study 9646426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g
Number of subjects: 1493
Study 9646426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3 g
Number of subjects: 1493
Study 9646426 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Azathioprine (PLA/AZA)
Number of subjects: 1493
Study 7837014 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Healon) used during adjustable suture surgery.
Number of subjects: 28
Study 7837014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hyaluronic acid) during adjustable suture surgery.
Number of subjects: 28
Study 3414406 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg) and hydrochlorothiazide (50 mg) (Moduretic)
Number of subjects: 58
Study 3414406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 31922432 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (0.2 mg/kg)
Number of subjects: 87
Study 31922432 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (1 mg/kg)
Number of subjects: 87
Study 31922432 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (0.2 mg/kg) and IV lidocaine (1 mg/kg)
Number of subjects: 87
Study 31922432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 31233407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (10 μg/kg intravenously)
Number of subjects: 16
Study 31233407 — intervention group
Group type: COMPARATOR
Intervention: Nonfentanyl (nitrous oxide and D-tubocurarine without fentanyl)
Number of subjects: 16
Study 28611110 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity progressive resistance training and impact loading programme for 8 months
Number of subjects: 0
Study 28611110 — intervention group
Group type: COMPARATOR
Intervention: Supervised machine-based isometric exercise training programme using the bioDensity system for 8 months
Number of subjects: 0
Study 28611110 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity progressive resistance training and impact loading programme
Number of subjects: 0
Study 28611110 — intervention group
Group type: COMPARATOR
Intervention: Supervised machine-based isometric exercise training programme using the bioDensity system
Number of subjects: 0
Study 26281053 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (1 mg twice daily) via transnasal nebulization for one week
Number of subjects: 50
Study 26281053 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (24 mg QD)
Number of subjects: 50
Study 23374898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg (R10)
Number of subjects: 46
Study 23374898 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 2.5 mg/day combined with Ezetimibe 10 mg/day (R2.5/E10)
Number of subjects: 46
Study 21474637 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week multidisciplinary group therapy program consisting of physical exercise and educational program
Number of subjects: 34